You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Anti-Fibrotic Therapy for Scleroderma/SSc

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is an autoimmune disorder characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, esophagus, intestine, and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,0 ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic Potential of PARP inhibitor for Acute Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Acute Pancreatitis (AP) is a potentially lethal inflammatory disease of the pancreas. Its pathogenesis remains obscure and is involved in a process of acute inflammation and necrosis in the pancreas, with variable involvement of regional tissues or organ systems that leads to a systemic inflammatory response. AP contributes to thousands of annual hospital admis ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Phase I Clinical Study Using an Antifibrotic Drug

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infection (hepatitis B and C), iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are exp ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Treatment for alcoholic liver disease

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leading cause of death in the United States and afflicts hundreds of millions of people worldwide. Alcohol intake remains the most important cause of l ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Therapeutic for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION: Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Current therapeutic strategies for the treatment of CKD include changes in life-style and/or medications to alleviate the underlying cause of disease. Since renal disease is ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Antifibrotic Therapy for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Chronic kidney disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. For decades, ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. PDGFR and KDR Inhibitors for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to tr ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic antibody fragments from glycoengineered Escherichia coli

    SBC: Glycobia, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Omalizumab (XolairTM) is a recombinant monoclonal anti-IgE antibody used in the fight against severe allergic asthma that generates 500 million per year. However, 2 out of every 1,000 patients treated with omalizumab suffer from anaphylaxis, a severe allergic reaction to the therapeutic. Moreover, omalizumab immunotherapy is prohibitively expensive, reaching n ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Conjugation of polysialic acid to biologics in glycoengineered Escherichia coli

    SBC: Glycobia, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Biotherapeutics currently constitute a 70 billion market, but their clinical efficacy is often compromised by limitations arising from proteolytic degradation, uptake by cells of the reticuloendothelial system, renal removal, and immunocomplex formation. This can lead to difficulties in reaching and maintaining effective therapeutic concentrations in the blood ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Generation of 3D root canals from two or more oral radiographs

    SBC: Imagination Software Corporation            Topic: NIDCR

    DESCRIPTION (provided by applicant): About 15 million root canals are performed each year in the United States. Failure rates are about 10%, with the failed initial treatment reflecting costs in the US of over 900 million dollars per year. While there are a number of causes of the failures, one of the primary causes is the inability to assess the difficulty of the root canal's morphology, i.e., it ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government